Warning: The NCBI web site requires JavaScript to function. more...
A new day dawns: women without oestrogen or is a balance best?
Jordan VC.
Breast Cancer Res. 2002;4(6):218-21. Epub 2002 Sep 10.
Related citations
[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B, Fourquet A, Pierga JY.
Bull Cancer. 2004 Dec;91(12):917-27. Review. French.
Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D, Ward S, De Nigris E, Simpson E, Carroll C, Wyld L.
Health Technol Assess. 2007 Jul;11(26):iii-iv, ix-xi, 1-134. Review.
The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators.
O'Regan RM, Jordan VC.
Lancet Oncol. 2002 Apr;3(4):207-14. Review.
Hormones 'R' us.
Sledge GW Jr.
Clin Breast Cancer. 2002 Jan;2(4):251. No abstract available.
Should aromatase inhibitors replace tamoxifen?
[No authors listed]
Drug Ther Bull. 2003 Aug;41(8):57-9. Review.
Role of antiestrogens and aromatase inhibitors in breast cancer treatment.
Bentrem DJ, Jordan VC.
Curr Opin Obstet Gynecol. 2002 Feb;14(1):5-12. Review.
Has tamoxifen had its day?
Baum M.
Breast Cancer Res. 2002;4(6):213-7. Epub 2002 Aug 27.
Selective oestrogen receptor modulators, aromatase inhibitors and the female breast.
Howell A.
Curr Opin Obstet Gynecol. 2005 Aug;17(4):429-34. Review.
Focus on anastrozole and breast cancer.
Mokbel K.
Curr Med Res Opin. 2003;19(8):683-8. Review.
The aromatase inhibitors in early breast cancer: who, when, and why?
Nordman IC, Spillane AJ, Hamilton AL.
Med J Aust. 2005 Jul 4;183(1):24-7. Review.
Benefit with aromatase inhibitors in the adjuvant setting for postmenopausal women with breast cancer.
Mouridsen HT, Robert NJ.
MedGenMed. 2005 Aug 24;7(3):20. Review.
Applicability of the intratumor aromatase preclinical model to predict clinical trial results with endocrine therapy.
Brodie AH, Mouridsen HT.
Am J Clin Oncol. 2003 Aug;26(4):S17-26. Review.
The therapeutic potential of aromatase inhibitors.
Miller WR, Jackson J.
Expert Opin Investig Drugs. 2003 Mar;12(3):337-51. Review.
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy?
Sainsbury R.
Br J Cancer. 2004 May 4;90(9):1733-9. Review.
Economic evaluation of the prevention and treatment of breast cancer--present status and open issues.
Imai H, Kuroi K, Ohsumi S, Ono M, Shimozuma K.
Breast Cancer. 2007;14(1):81-7. Review.
Current and future status of adjuvant therapy for breast cancer.
Coleman RE.
Cancer. 2003 Feb 1;97(3 Suppl):880-6. Review.
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.
Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group.
Lancet. 2005 Jan 1-7;365(9453):60-2.
The Breast International Group 1-98 trial: big results for women with hormone-sensitive early breast cancer.
Monnier AM.
Expert Rev Anticancer Ther. 2007 May;7(5):627-34. Review.
Anastrozole.
Cuzick J.
Drugs Today (Barc). 2005 Apr;41(4):227-39. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on